Dr. Aby J. Mathew, Sr. Vice President of BioLife Solutions to present Cell therapy and Cell Culture: Bioprocessing Conference
One of the most influential and pioneering figures in Cell and Gene therapy, Dr. Aby J. Mathew, is set to present on 'Bio-preservation & bio-logistics considerations for GMP regenerative medicine manufacturing and delivery' at the Cell Culture and Cell Therapy: Bioprocessing Conference.
- (1888PressRelease) March 23, 2017 - Philadelphia, USA - Dr. Aby J. Mathew of BioLife Solutions has confirmed his presence as one of the key speakers at the Cell Culture and Cell Therapy: Bioprocessing Conference, taking place at the Radisson Hotel Philadelphia Northeast in Pennsylvania, USA. The conference, to be held on June 26 - 27, 2017, will offer a combination of keynote presentations, panel discussions, and case studies that will delve into the latest trends emerging in cell and gene therapy manufacturing.
Dr. Mathew is Sr. Vice President & Chief Technology Officer of BioLife Solutions and has been a member of: AABB, BEST Collaborative, ISCT, ARM, TERMIS, and the Society for Cryobiology. He will present on 'Bio-preservation & bio-logistics considerations for GMP regenerative medicine manufacturing and delivery' at the conference, a topic that will look at the best practices in optimizing bio-preservation for GMP manufacturing, storage, delivery, and patient application.
Recently, in a short pre-event interview with MarketsandMarkets, speaking about his presentation and the insights that it would provide, Dr. Mathew said, "In addition to my presentation, there is also a presentation from Dr. John M. Baust, who is the President and CEO of CPSI Biotech. Between our two presentations, attendees should walk away with a very clear understanding of why we see loss of cell yield, viability, and function, following cryopreservation and hypothermic preservation as a result of Delayed Onset Cell Death."
Dr. Mathew also spoke about emerging research areas in cell culture bioprocessing for process development and control. He said, "The emerging areas of development are related to the various steps in the process workflow, and what tools and methods support the workflow. Starting with source material, there is emerging interest in extending the stability of tissue biopsies, bone marrow, and apheresis products. Even for cell banks that seed bioreactors, there is growing interest in maintaining high density cell stocks, and then achieving cryopreserved seed stocks that could enable faster logarithmic growth curves, while maintaining cell functional responses. Within the culture conditions, there is ongoing interest in optimizing cell culture media, but also integrating that cell culture media optimization with a Quality/Regulatory footprint that supports using those cell products for clinical applications."
The conference is supported by the BioPharma Research Council, Global Institute of Stem Cell Therapy and Research, Irish Stem Cell Foundation, Biotech Research Society - India, RegMedNet and United Kingdom Society for Biomaterials (UKSB). With participation from experts of cellular therapy, gene therapy, and cell engineering, from pharma, bio pharma organizations, universities and academic institutions, the congress will be an excellent opportunity not only to stay abreast of all the latest developments but also overcome any challenges that are being currently faced.
Topics to be covered at the conference include fermentation technologies and device technologies for bioprocessing of cell culture, next generation cellular models, process development for next generation bio-therapeutics, ex-vivo gene therapy application, C-GMP compliance guideline, FDA approvals and regulatory policies. Biospherix and Essential Pharmaceuticals have confirmed their presence at the conference and will be showcasing their latest offerings.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam